Apollomics (APLM) Total Non-Current Liabilities (2021 - 2025)
Apollomics (APLM) posted quarterly Total Non-Current Liabilities of $3.6 million for Q4 2025, up 131.46% quarter-over-quarter from $1.5 million in Q2 2023.
Apollomics (APLM) Total Non-Current Liabilities (2021 - 2025) Analysis & Trends
Apollomics (APLM) has reported Total Non-Current Liabilities for 4 consecutive years, with $3.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Total Non-Current Liabilities changed N/A year-over-year to $3.6 million; the TTM figure through Dec 2025 stood at $3.6 million (changed N/A YoY), while the FY2025 annual figure was $3.6 million, up 51185.71% from the prior year.
- Total Non-Current Liabilities climbed to $3.6 million in Q4 2025 per APLM's latest filing, from $1.5 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $512.2 million in Q4 2022 and bottomed at $1.5 million in Q2 2023.
- Historically, Total Non-Current Liabilities has averaged $210.0 million across 4 years, with a median of $163.2 million in 2021.
- On a YoY basis, Total Non-Current Liabilities climbed as much as 58.71% in 2022 and fell as far as 58.71% in 2022.
- Apollomics' Total Non-Current Liabilities stood at $322.7 million in 2021, then surged by 58.71% to $512.2 million in 2022, then plunged by 99.7% to $1.5 million in 2023, then surged by 131.46% to $3.6 million in 2025.
- Business Quant data shows APLM's Total Non-Current Liabilities at $3.6 million in Q4 2025, $1.5 million in Q2 2023, and $512.2 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.78 Bn | 131.93 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 86.58 Bn | 78.59 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 65.29 Bn | 60.11 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.86 Bn | 53.73 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 42.12 Bn | 37.02 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.73 Bn | 28.42 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.19 Bn | 9.80 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 9.32 Bn |
| 10 | Apollomics | 34.67 Mn | 31.39 Mn | - | 3.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.58 Mn |
| Jun 30, 2023 | 1.55 Mn |
| Dec 31, 2022 | 512.24 Mn |
| Dec 31, 2021 | 322.74 Mn |